Povetacicept
Recombinant proteinexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT05034484)
Timeline
Indications
Studied for
- Anemia, Hemolytic, Autoimmune · Phase 1/Phase 2
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Phase 1/Phase 2
- Glomerulonephritis, IGA · Phase 3
- Glomerulonephritis, Membranous · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Kidney Diseases · Phase 2/Phase 3
- Lupus Nephritis · Phase 1/Phase 2
- Purpura, Thrombocytopenic, Idiopathic · Phase 1/Phase 2
Mechanism of action
TNFSF13B inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095306 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07204275 | Phase 2/Phase 3 (Phase 3) | Sep 30, 2025 | Vertex |
| NCT07010406 | Phase 1 | Jun 6, 2025 | Vertex |
| NCT06564142 | Phase 3 | Aug 30, 2024 | Vertex |
| NCT05757570 | Phase 1/Phase 2 (Phase 2) | Jul 3, 2023 | Alpine Immune Sciences |
| NCT05732402 | Phase 1/Phase 2 (Phase 2) | Mar 15, 2023 | Alpine Immune Sciences |
| NCT05034484 | Phase 1 | Nov 30, 2021 | Alpine Immune Sciences |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alpine Immune Sciences | For profit | 3 | 3 | 2 | 2021 |
| Vertex | For profit | 3 | 3 | 2 | 2024 |
2 organizations
Page 1 / 1